



GoodRx Offers Discounts of Up to 43% On Fertility Treatments

May 22, 2024

In 2023, Americans saved over \$6 million on fertility medications using GoodRx

SANTA MONICA, Calif.--(BUSINESS WIRE)--May 22, 2024-- [GoodRx](#), the leading destination for prescription savings in the U.S., today announced it is [offering discounts](#) of up to 43% on fertility treatments based on the best available GoodRx price,¹ including savings on generic and brand-name medications used during every phase of the in vitro fertilization (IVF) process. These discounts can help manage the high costs that families and individuals face when trying to expand their families.

Cost is one of the major challenges patients face during their fertility treatment. A single cycle of IVF can range from \$15,000 to \$30,000 or more on average. Much of this cost is driven by the [multiple medications](#) needed during an entire IVF cycle, some of which are only available to purchase as individual doses. Plus, many patients will need to go through more than one IVF cycle, multiplying their treatment expenses. While employers are increasingly adding fertility and family forming benefits, for many, insurance rarely covers the full cost of treatment, leaving patients to either shoulder a large financial burden or forgo treatment altogether.

"Hundreds of thousands of people every year are faced with an incredibly challenging decision: do I reevaluate my plans to expand my family, or pay thousands of dollars to pursue fertility treatments? GoodRx is here to relieve some of that financial burden and take some of the stress out of the reproductive journey," said Dorothy Gemmell, Chief Commercial Officer, GoodRx. "Through savings on both generic and brand-name medications, GoodRx helps users afford their fertility treatments so fewer people have to choose between their future and their finances."

Below is a sampling of the medication discounts available for each phase of IVF: Suppression, Stimulation, Triggering, and Implantation

Drug Name	Out of Pocket Package Price*	GoodRx Price**	Avg % Savings with GoodRx
Suppression			
Fyremadel	\$105	\$52	50%
Ganirelix	\$260	\$67	74%
Leuprolide	\$868	\$115	87%
Stimulation			
Clomid	\$90	\$68	25%
Clomiphene	\$75	\$30	60%
Letrozole	\$330	\$22	93%
Triggering			
Novarel	\$228	\$159	30%
Ovidrel	\$293	\$221	25%
Pregnyl	\$172	\$122	29%
Implantation			
Crinone	\$678	\$235	37%
Endometrin	\$399	\$289	28%
Progesterone	\$50 - \$90	\$13 - \$23	55% - 82%

*Price is based on the smallest unit of the medication that a patient can purchase; prices will vary based on how many units are required for the number of doses needed. **GoodRx prices are based on the lowest available price as of April 2024.

Learn more from trusted doctors, pharmacists and health experts

Fertility medications and the IVF process can be complicated and hard to understand. To further support consumers who are on their fertility journey, or simply looking to learn more, GoodRx has created the [GoodRx Fertility Hub](#), which offers credible, timely, and actionable information to help people learn more about the fertility process, get information about common concerns, uncover treatment options, and access significant savings. Each article is researched and written by a team of editorial experts, and clinical content is written and reviewed by a team of medical experts that includes physicians, pharmacists, and more.

To find savings and trusted health information, download the GoodRx app or go to <https://www.goodrx.com/go/fertility>.

About GoodRx

GoodRx is the leading destination for prescription savings in the U.S. We offer consumers free access to transparent and lower prices for generic and brand medications, as well as comprehensive healthcare research and information. We also equip healthcare professionals with efficient ways to find and prescribe affordable medications. Since 2011, GoodRx has helped consumers save nearly \$75 billion and is one of the most downloaded medical apps over the past decade.

GoodRx periodically posts information that may be important to investors on its investor relations website at <https://investors.goodrx.com>. We intend to use our website as a means of disclosing material nonpublic information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors and potential investors are encouraged to consult GoodRx's website regularly for important information, in addition to following GoodRx's press releases, filings with the Securities and Exchange Commission (the "SEC") and public conference calls and webcasts. The information contained on, or that may be accessed through, GoodRx's website is not incorporated by reference into, and is not a part of, this press release.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding consumer savings; the benefits of our offerings to consumers and GoodRx; and our plans, expectations and objectives. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, risks relating to our ability to attract and retain talent and the important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2023, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

¹ Based on the best available GoodRx price available at participating pharmacies as of April 2024.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20240522443600/en/): <https://www.businesswire.com/news/home/20240522443600/en/>

Media Contact
press@goodrx.com

Source: GoodRx